Response to DNA-damaging agents and PARP inhibitors in ATM mutated metastatic colorectal cancer: case series

This series underscores the sensitivity of ATM-mutated mCRC to DNA-damaging chemotherapy and highlights the potential role of PARPi. The therapeutic benefit of PARPi in these patients cannot be fully separated from concurrent chemotherapy, and the observed responses are likely to reflect combined effects. Nonetheless, these findings suggest potential synergy and warrant further investigation of PARP inhibition, alone or in combination, in biomarker-selected mCRC populations.